Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study.

被引：0
|
作者：
Hao, Chunfang [1 ]
Wang, Xu [1 ]
Shi, Yehui [1 ]
Tong, Zhongsheng [1 ]
Li, Shufen [1 ]
Liu, Xiaodong [1 ]
Zhang, Lan [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1033
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial
    Huang, Xiang
    Jin, Nan
    Sun, Chunxiao
    Yan, Xueqi
    Yang, Fan
    Liang, Yan
    Li, Wei
    Yin, Yongmei
    CANCER RESEARCH, 2024, 84 (09)
  • [2] Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
    Jiang, Kuikui
    Hong, Ruoxi
    Xia, Wen
    Lu, Qianyi
    Li, Liang
    Huang, Jianhao
    Shi, Yanxia
    Yuan, Zhongyu
    Zheng, Qiufan
    An, Xin
    Xue, Cong
    Huang, Jiajia
    Bi, Xiwen
    Chen, Meiting
    Zhang, Jingmin
    Xu, Fei
    Wang, Shusen
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 513 - 521
  • [3] Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study
    Q. Li
    H. Li
    H. Jiang
    Y. Feng
    Y. Cui
    Y. Wang
    Y. Ji
    Y. Yu
    W. Li
    C. Xu
    S. Yu
    R. Zhuang
    T. Liu
    Clinical and Translational Oncology, 2018, 20 : 695 - 702
  • [4] Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study
    Li, Q.
    Li, H.
    Jiang, H.
    Feng, Y.
    Cui, Y.
    Wang, Y.
    Ji, Y.
    Yu, Y.
    Li, W.
    Xu, C.
    Yu, S.
    Zhuang, R.
    Liu, T.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 695 - 702
  • [5] Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study
    Liu, Jiaxuan
    He, Maiyue
    Jiang, Mingxia
    Zhou, Shihan
    Zhang, Mengqi
    Li, Yiqun
    Chen, Shanshan
    Cai, Ruigang
    Mo, Hongnan
    Lan, Bo
    Ma, Fei
    Xu, Binghe
    Li, Qiao
    BMC CANCER, 2024, 24 (01)
  • [6] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Min Yan
    Limin Niu
    Huimin Lv
    Mengwei Zhang
    Jing Wang
    Zhenzhen Liu
    Xiuchun Chen
    Zhenduo Lu
    Chongjian Zhang
    Huiai Zeng
    Shengnan Zhao
    Yajing Feng
    Huihui Sun
    Huajun Li
    Nature Communications, 14
  • [7] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Yan, Min
    Niu, Limin
    Lv, Huimin
    Zhang, Mengwei
    Wang, Jing
    Liu, Zhenzhen
    Chen, Xiuchun
    Lu, Zhenduo
    Zhang, Chongjian
    Zeng, Huiai
    Zhao, Shengnan
    Feng, Yajing
    Sun, Huihui
    Li, Huajun
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Cao, Jun
    Teng, Yuee
    Li, Huiping
    Zhang, Lili
    Ouyang, Quchang
    Xie, Weimin
    Pan, Yueyin
    Song, Zhenchuan
    Ling, Xiaoling
    Wu, Xiaohong
    Xu, Jingwei
    Li, Li
    Ren, Liping
    Wang, Hong
    Zhou, Dongxian
    Luo, Jing
    Hu, Xichun
    BMC MEDICINE, 2023, 21 (01)
  • [9] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Jun Cao
    Yuee Teng
    Huiping Li
    Lili Zhang
    Quchang Ouyang
    Weimin Xie
    Yueyin Pan
    Zhenchuan Song
    Xiaoling Ling
    Xiaohong Wu
    Jingwei Xu
    Li Li
    Liping Ren
    Hong Wang
    Dongxian Zhou
    Jing Luo
    Xichun Hu
    BMC Medicine, 21
  • [10] Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells
    Parsons, Heather A.
    Macrae, Erin R.
    Guo, Hao
    Li, Tianyu
    Barry, William T.
    Tayob, Nabihah
    Wulf, Gerburg M.
    Isakoff, Steven J.
    Krop, Ian E.
    JCO PRECISION ONCOLOGY, 2021, 5 : 896 - 903
12345